ChiCTR1900028620 版本V1.0 版本创建时间2019/12/29 13:08:28 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900028620 

最近更新日期:

Date of Last Refreshed on:

2019-12-29 13:08:01 

注册时间:

Date of Registration:

2019-12-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

外泌体在急性肺损伤发生发展中的机制研究

Public title:

The Role of Exosomes in Acute Lung Injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

外泌体在急性肺损伤发生发展中的机制研究

Scientific title:

The mechanism of exosomes in the development of acute lung injury

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

楚玉峰 

研究负责人:

楚玉峰 

Applicant:

Yufeng Chu 

Study leader:

Yufeng Chu 

申请注册联系人电话:

Applicant telephone:

+86 86 15168886138

研究负责人电话:

Study leader's
telephone:

+86 531-68777920

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chunancy@163.com

研究负责人电子邮件:

Study leader's E-mail:

chuyufengsh@aliyun.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市经五路324号

研究负责人通讯地址:

山东省济南市经五路324号

Applicant address:

324 Jingwu Road, Ji'nan, Shandong, China

Study leader's address:

324 Jingwu Road, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东省立医院重症医学二科

Applicant's institution:

Shandong Provincial Hospital

研究负责人所在单位:

山东省立医院重症医学二科

Affiliation of the Leader:

Shandong Provincial Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SWYX:No.2019-199

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东省立医院涉及人的生物医学研究伦理委员会

Name of the ethic committee:

Biomedical Research Ethics Committee of Shandong Provincial Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2019-12-03 00:00:00

伦理委员会联系人:

周小明

Contact Name of the ethic committee:

Xiaoming Zhou

伦理委员会联系地址:

山东省济南市经五路324号

Contact Address of the ethic committee:

324 Jingwu Road, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东省立医院

Primary sponsor:

Shandong Provincial Hospital

研究实施负责(组长)单位地址:

山东省济南市经五路324号

Primary sponsor's address:

324 Jingwu Road, Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东省立医院

具体地址:

经五路324号

Institution
hospital:

Shandong Provincial Hospital

Address:

324 Jingwu Road

经费或物资来源:

山东省科技厅

Source(s) of funding:

Shandong Science and Technology Department

研究疾病:

急性肺损伤  

Target disease:

Acute Lung Injury

研究疾病代码:

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

观察肺泡灌洗液及血清中外泌体在急性肺损伤患者发生发展不同时期的表达变化规律。  

Objectives of Study:

To observe the expression of exosomes in BALF and serum at different stages of the development of acute lung injury.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.年龄≥18岁;
2.符合2012柏林ARDS诊断标准患者;
3.签署知情同意书

Inclusion criteria

1. Aged >= 18 years old;
2. Patients who meet the Berlin ARDS diagnostic standard in 2012;
3. Sign informed consent

排除标准:

1. 孕妇、肿瘤及免疫系统疾病患者;
2. 存在纤支镜检查禁忌(氧合差/严重心脏病,心功能不全/凝血异常,大量咯血/主动脉瘤,有破裂危险等);

Exclusion criteria:

1. Pregnant women, patients with tumor and immune system diseases;
2. There are some contraindications (poor oxygenation / serious heart disease, cardiac insufficiency / coagulation abnormality, massive hemoptysis / aortic aneurysm, risk of rupture, etc.) in fibrobronchoscopy;

研究实施时间:

Study execute time:

From 2020-01-10 00:00:00 To 2023-01-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-01-10 00:00:00 To 2022-10-10 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

200

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东省立医院 

单位级别:

三级甲等 

Institution
hospital:

Shandong Provincial Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

济南市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Jinan Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海瑞金医院北院 

单位级别:

三级甲等 

Institution
hospital:

Shanghai Ruijin Hospital North Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

miR210

指标类型:

主要指标

Outcome:

miR210

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

肺泡灌洗液

组织:

Sample Name:

BALF

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 不限 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向申办方申请

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Apply to Sponsor

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2019-12-29 13:08:01